Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
REGULATORY Jaypirca, Prevymis, Relvar and More on MHLW Panel Agenda for May 9
April 26, 2024
-
BUSINESS Ono Ties Up with PRISM BioLab in Oncology Drug Discovery
April 26, 2024
-
BUSINESS Argenx Seeks Label Expansion for Vyvdura in Japan
April 26, 2024
-
BUSINESS Janssen Files Tremfya for Ulcerative Colitis in Japan
April 26, 2024
-
BUSINESS Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
April 26, 2024
-
BUSINESS Chugai’s Q1 Sales Drop 24% on End of Ronapreve Govt Purchase and Generic Competition
April 25, 2024
-
REGULATORY Regulation Panel’s Final Report Specifies Exemptions for All-Case PMS
April 25, 2024
-
REGULATORY Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod
April 25, 2024
-
BUSINESS Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
-
REGULATORY BMS’s Sotyktu to Face Price Cuts under CEA Scheme
April 25, 2024
-
BUSINESS Astellas Reels in EU Nod for Xtandi Use in Earlier Setting
April 25, 2024
-
BUSINESS Novo Japan’s Revenue Hits Record Yet Again in 2023 with 8.5% Growth
April 25, 2024
-
BUSINESS Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
-
ORGANIZATION Policymakers Prod for Industry’s Concrete Actions Toward Eliminating Drug Loss
April 24, 2024
-
ORGANIZATION Govt Should Buy Up Domestic Antibiotic APIs, Cost 5-8 Times Higher: Industry Official
April 24, 2024
-
REGULATORY Lawmakers’ League for Generics to Urge Rethink of Off-Year Price Revisions to Health Minister
April 24, 2024
-
BUSINESS Teijin to Copromote CureApp’s Hypertension Therapy App
April 24, 2024
-
BUSINESS Pfizer’s PARP Inhibitor Talzenna Now Available in Japan
April 24, 2024
-
BUSINESS Bayer Poised to Navigate Patent Cliff with Blockbuster Hopefuls for Stroke, Kidney Disease
April 24, 2024
-
REGULATORY 12 Quasi-Original Drugs to Be Excluded from New Coverage Scheme
April 23, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…